See what’s new.
Duke Inventions Return a Record $115M Revenue in FY25, Highlighting Momentum in Research Translation
OTC reports highest-ever revenue as invention disclosures rise, while Duke Capital Partners delivers its strongest investment year ever.
The Translational Matchmakers: How Technology Marketing Connects Inventors with Industry
At OTC, the Technology Marketing team plays a pivotal role in moving discoveries beyond the lab.
Duke University ranks 24th worldwide for patents granted to academic institutions
Duke researchers are pioneering inventors and Duke is successfully commercializing these inventions for the benefit of the public.
Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs
Tune Therapeutics is a Duke University start-up and Duke Capital Partners portfolio company developing epigenetic editing spun out of the lab of co-founder Professor Charles Gersbach (BME, Pratt).
Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
Humacyte is a Duke University start-up out of the lab of Dr. Laura Niklason (formerly Anesthesiology, SOM), co-founded with Drs. Juliana Blum and Shannon Dahl.
Invented at Duke 2024 showcases the past and present of innovation at Duke, promising a bright future
A special Centennial edition of Invented at Duke featured inventors and innovations from the past, present, and future of Duke.
Duke Inventions Bring $82.6M in Revenue and Launch 6 New Start-Ups
$82.6M in revenue. 94 patents issued. 302 new invention disclosures. In a down year for new disclosures, OTC focuses on investing in the future.
Duke Inventions Returned $102 Million to Inventors and the University in FY23
Fifteen new companies and expanded capacity for Office for Translation & Commercialization showcased in the FY23 annual report.
Gilhuly Accelerator Fund Invests Over $1M in Duke Inventor Projects in its Inaugural Year
The Duke community, led by Trustee Ned Gilhuly, is supporting Duke inventors with its newest translational fund dedicated to accelerating the development of early-stage technologies with high commercial potential.